GlassScriptPhysician profile
Froilan M Francisco
NPI 1568600971
$4,436.65
in general payments reported to CMS, 2019-2025
23 companies · $812 in 2025
The $812 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $421 · 2021: $153 · 2022: $618 · 2023: $396 · 2024: $988 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,076.19 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $694.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $667.77 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $384.64 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.60 | 2019-2022 | |
| Gilead Sciences, INC. | $229.86 | 2022-2024 | Epclusa |
| Merck Sharp & Dohme LLC | $153.40 | 2021-2022 | |
| Abbott Laboratories | $122.64 | 2023-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $105.63 | 2022 | |
| Astellas Pharma US INC | $99.99 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.66 | 2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $90.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $74.32 | 2020-2021 | |
| Pfizer INC. | $72.06 | 2019 | |
| Exact Sciences Corporation | $65.93 | 2024-2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $58.93 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $36.17 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.88 | 2022 | |
| Abbvie INC. | $26.32 | 2022 | |
| Boston Scientific Corporation | $20.63 | 2021 | |
| Antares Pharma, INC. | $17.97 | 2024 | Xyosted |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Froilan Francisco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.